Hyperbaric Oxygen Therapy - Hyperbaric Chamber Information ...
Hyperbaric Oxygen Therapy - Hyperbaric Chamber Information ...
Hyperbaric Oxygen Therapy - Hyperbaric Chamber Information ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Sensitivity analysis<br />
Table 83 shows the results of the sensitivity analysis varying the efficacy of the<br />
comparator group using the 95% CI, costs of a doctor in attendance during treatment,<br />
varying the number of HBOT sessions per patient and the number of chambers in the<br />
facility.<br />
Table 83 Sensitivity analysis – osteoradionecrosis<br />
Sensitivity Analysis Incremental cost per case of osteoradionecrosis avoided<br />
$28,480 – primary case<br />
15.87% of patients in the comparator group with<br />
$66,187<br />
osteoradionecrosis (lower 95% CI)<br />
46.98% of patients in the comparator group with<br />
osteoradionecrosis (upper 95% CI)<br />
Cost of doctor/specialist covered by cost of patient<br />
assessment prior to a course of HBOT treatment<br />
$16,663<br />
$18,438<br />
15 HBOT sessions per patient $14,212<br />
40 HBOT sessions per patient $37,991<br />
Operating costs shared between 2 HBOT units $16,214<br />
Operating costs shared between 4 HBOT units $10,081<br />
Table 83 shows that if the staff requirements of a hyperbaric nurse, technician and<br />
physician are shared among four HBOT chambers in a hyperbaric facility, the<br />
incremental cost per case of osteoradionecrosis avoided is $10,081. The incremental cost<br />
per case of osteoradionecrosis avoided is $66,187, using the lower limit of the 95% CI<br />
for the efficacy of the comparator group, keeping the efficacy of the HBOT group fixed.<br />
Summary<br />
The incremental treatment cost per case of osteoradionecrosis avoided is estimated to be<br />
$28,480, in patients who had an indication for removal of one or more teeth in a segment<br />
of the mandible. Sensitivity analysis suggests a range of $10,081-$66,187 per case of<br />
osteoradionecrosis avoided.<br />
Conclusions<br />
The indicative cost-effective ratios estimated for a small number of indications i.e.<br />
HBOT in diabetic wounds, necrotising soft tissue infections, and osteoradionecrosis, are<br />
summarised in Table 84.<br />
Table 84 Summary of indicative cost-effectiveness ratios in four indications<br />
Diabetic Wounds<br />
- Incremental Cost per Amputation Avoided $22,054 (cost saving to $63,100)<br />
Non-Diabetic Wounds<br />
Treatment cost of $6,941 per patient for a one third<br />
- Reduction in Wound Area<br />
reduction in wound area<br />
Incremental Cost per Death Avoided<br />
- Necrotising Soft Tissue Infections<br />
$16,105 ($5,368-$71,557)<br />
Incremental Cost per Case of Osteoradionecrosis Avoided $28,480 ($10,081-$66,187)<br />
In addition:<br />
<strong>Hyperbaric</strong> oxygen therapy 89